What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?
暂无分享，去创建一个
R. Larson | M. Baccarani | G. Martinelli | D. Niederwieser | R. Silver | R. Conti | F. Mahon | W. Padula | R. Hehlmann | C. Schiffer | F. Guilhot | J. Apperley | B. Simonsson | J. Mayer | J. Guilhot | S. Saussele | E. Eigendorff | M. Mueller